BNP Paribas Financial Markets’s X4 Pharmaceuticals XFOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $76.5K | Buy |
16,384
+11,628
| +244% | +$47.7K | ﹤0.01% | 4690 |
|
|
2026
Q1 | $19.6K | Buy |
4,756
+4,245
| +831% | +$15.9K | ﹤0.01% | 5094 |
|
|
2025
Q4 | $2.04K | Sell |
511
-43
| -8% | -$156 | ﹤0.01% | 5347 |
|
|
2025
Q3 | $1.9K | Sell |
554
-82
| -13% | -$211 | ﹤0.01% | 5174 |
|
|
2025
Q2 | $1.21K | Sell |
636
-6
| -0.9% | -$25 | ﹤0.01% | 5122 |
|
|
2025
Q1 | $4.55K | Sell |
642
-335
| -34% | -$4.61K | ﹤0.01% | 4869 |
|
|
2024
Q4 | $21.5K | Sell |
977
-380
| -28% | -$6.06K | ﹤0.01% | 4708 |
|
|
2024
Q3 | $27.2K | Buy |
1,357
+787
| +138% | +$16.4K | ﹤0.01% | 3716 |
|
|
2024
Q2 | $9.91K | Sell |
570
-1,483
| -72% | -$48.5K | ﹤0.01% | 3727 |
|
|
2024
Q1 | $85.6K | Sell |
2,053
-7,398
| -78% | -$206K | ﹤0.01% | 3473 |
|
|
2023
Q4 | $238K | Buy |
9,451
+7,896
| +508% | +$192K | ﹤0.01% | 3136 |
|
|
2023
Q3 | $50.8K | Buy |
1,555
+484
| +45% | +$21.1K | ﹤0.01% | 3462 |
|
|
2023
Q2 | $62.3K | Buy |
+1,071
| New | +$55K | ﹤0.01% | 3405 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 3823 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 4005 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 4700 |
|
|
2022
Q2 | – | Sell |
-5
| Closed | -$190 | – | 4068 |
|
|
2022
Q1 | $280 | Sell |
5
-4
| -44% | -$229 | ﹤0.01% | 4069 |
|
|
2021
Q4 | $637 | Sell |
9
-1
| -10% | -$126 | ﹤0.01% | 4092 |
|
|
2021
Q3 | $1.56K | Sell |
10
-5
| -33% | -$823 | ﹤0.01% | 3832 |
|
|
2021
Q2 | $3K | Sell |
15
-172
| -92% | -$43.2K | ﹤0.01% | 3841 |
|
|
2021
Q1 | $48.3K | Buy |
187
+84
| +82% | +$22.1K | ﹤0.01% | 3618 |
|
|
2020
Q4 | $19.9K | Sell |
103
-17
| -14% | -$3.34K | ﹤0.01% | 3850 |
|
|
2020
Q3 | $24.4K | Buy |
120
+100
| +500% | +$24K | ﹤0.01% | 3764 |
|
|
2020
Q2 | $5.64K | Sell |
20
-135
| -87% | -$37K | ﹤0.01% | 3957 |
|
|
2020
Q1 | $46.5K | Buy |
155
+99
| +177% | +$28.1K | ﹤0.01% | 3569 |
|
|
2019
Q4 | $17.9K | Buy |
56
+21
| +60% | +$7.53K | ﹤0.01% | 4031 |
|
|
2019
Q3 | $13.5K | Buy |
35
+32
| +1,067% | +$12.7K | ﹤0.01% | 4093 |
|
|
2019
Q2 | $1.54K | Buy |
+3
| New | +$1.52K | ﹤0.01% | 4343 |
|
|
2019
Q1 | – | Hold |
0
| – | -$158 | – | 4426 |
|
|
2018
Q4 | – | Sell |
-1
| Closed | -$382 | – | 4128 |
|
|
2018
Q3 | $237 | Hold |
1
| – | – | ﹤0.01% | 4365 |
|
|
2018
Q2 | $530 | Sell |
1
-3
| -75% | -$9.82K | ﹤0.01% | 4323 |
|
|
2018
Q1 | $18.2K | Buy |
+4
| New | +$11.6K | ﹤0.01% | 3942 |
|
Other funds holding XFOR
EAM
VCM
VFT
VPM
BNP Paribas Financial Markets's XFOR Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its X4 Pharmaceuticals (XFOR) stake by 244% in Q2 2026, buying an estimated $47.7K and bringing the position to 16,384 shares worth $76.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4690.
BNP Paribas Financial Markets first reported a position in XFOR in Q1 2018 and has held it in 28 quarters since. The position peaked at $238K in Q4 2023. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.
- BNP Paribas Financial Markets held 16,384 shares of X4 Pharmaceuticals worth $76.5K as of Q2 2026.
- BNP Paribas Financial Markets bought 11,628 X4 Pharmaceuticals shares in Q2 2026, an estimated $47.7K.
- X4 Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4690 holding.
- BNP Paribas Financial Markets first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 28 quarters since.
- BNP Paribas Financial Markets's X4 Pharmaceuticals position peaked at $238K in Q4 2023.
- 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.